We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

146 hedge funds and large institutions have $460M invested in iTeos Therapeutics in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more call options, than puts

Call options by funds: $1.38M | Put options by funds: $1.01M

21% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 47

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3.51% less ownership

Funds ownership: 100.73% → 97.22% (-3.5%)

5% less funds holding

Funds holding: 153 → 146 (-7)

6% less capital invested

Capital invested by funds: $489M → $460M (-$28.4M)

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

Holders
146
Holders Change
-7
Holders Change %
-4.58%
% of All Funds
2.29%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
57
Reduced
47
Closed
25
Calls
$1.38M
Puts
$1.01M
Net Calls
+$367K
Net Calls Change
+$993K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$4.25M
2
BlackRock
BlackRock
New York
+$3.09M
3
Goldman Sachs
Goldman Sachs
New York
+$2.93M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$2.44M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.32M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$7.21M
2
Morgan Stanley
Morgan Stanley
New York
-$5.51M
3
Invesco
Invesco
Georgia
-$5.32M
4
State Street
State Street
Massachusetts
-$3.74M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$62M +$3.09M +216,888 +5%
RCM
2
RA Capital Management
Massachusetts
$58.5M – – –
MAM
3
MPM Asset Management
Massachusetts
$36.3M – – –
BC
4
Boxer Capital
California
$28.5M – – –
BI
5
BVF Inc
California
$24M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$23.5M +$5.18K +363 +0%
MB
7
MPM BioImpact
Massachusetts
$23.1M – – –
State Street
8
State Street
Massachusetts
$20.7M -$3.74M -262,189 -14%
Citadel Advisors
9
Citadel Advisors
Florida
$15.8M -$3.54M -248,231 -17%
Millennium Management
10
Millennium Management
New York
$10.9M +$4.25M +297,830 +56%
Goldman Sachs
11
Goldman Sachs
New York
$8.52M +$2.93M +205,556 +47%
SVCM
12
Saturn V Capital Management
Texas
$8.42M +$2.22M +155,505 +32%
CS
13
Candriam SCA
Luxembourg
$8.1M -$1.82M -127,970 -17%
OCA
14
Octagon Capital Advisors
New York
$7.89M – – –
6CM
15
683 Capital Management
New York
$7.75M +$1.5M +105,000 +22%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$7.66M +$2.32M +163,043 +39%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$6.65M +$296K +20,773 +4%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$6.49M -$350K -24,545 -5%
Renaissance Technologies
19
Renaissance Technologies
New York
$5.47M +$1.19M +83,300 +25%
AG
20
Artal Group
Luxembourg
$5.3M – – –
Barclays
21
Barclays
United Kingdom
$4.17M +$826K +57,924 +23%
Prudential Financial
22
Prudential Financial
New Jersey
$3.85M +$1.91M +133,690 +85%
Northern Trust
23
Northern Trust
Illinois
$3.53M +$211K +14,819 +6%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$3.47M -$1.23K -86 -0%
Citigroup
25
Citigroup
New York
$3.11M -$773K -54,218 -19%
1
2 3 4 5

ITOS Hedge Fund Activity: Q2 2023 in Review

146 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q2 2023, worth a combined $460M — down 5.8% from $489M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of ITOS and 18 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 57 added.

The largest buyer was Millennium Management, adding an estimated $4.25M. The largest seller was JP Morgan Chase, cutting an estimated $7.21M.

  • 146 institutional investors held iTeos Therapeutics (ITOS) as of Q2 2023, down from 153 in Q1 2023.
  • Funds reported $460M of iTeos Therapeutics stock for Q2 2023, down 5.8% quarter-over-quarter.
  • 18 funds opened new iTeos Therapeutics positions in Q2 2023 and 25 closed out, a net change of -7 holders.
  • The largest iTeos Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $4.25M added.
  • The largest iTeos Therapeutics seller in Q2 2023 was JP Morgan Chase, an estimated $7.21M sold.

Based on aggregated 13F filings for Q2 2023.